Medical Doctor Program year 2024 Source: CMS Open Payments, 2026 publication

Chia-Yuan Hsu

Internal Medicine Saint Louis, MO Medical Doctor

NPI 1154909828 CMS profile 11655732

3721 S Grand Blvd, Saint Louis, MO 63118

Open in the dashboard

General payments

$467

13 records reported · program year 2024

Research payments

$0

Paid to them · None reported · program year 2024

Ownership & investment interest

$0

None reported

Through program year 2024, Chia-Yuan Hsu of Saint Louis, MO is reported in the CMS Open Payments database as having received $467 across 13 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 58th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

1 row
Year Kind Relative to this record's peak year Amount Records
2024 General $467 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Chia-Yuan Hsu
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Chia-Yuan Hsu were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Chia-Yuan Hsu Internal Medicine median Middle half National median
2019 $0 $159 $48–$570 $163
2020 $0 $119 $33–$402 $114
2021 $0 $135 $37–$521 $132
2022 $0 $141 $42–$496 $149
2023 $0 $149 $45–$519 $160
2024 $467 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program year 2024
  1. Amgen Inc. $152 5 payments
  2. Lilly USA, LLC $96 1 payment
  3. Alexion Pharmaceuticals, Inc. $90 3 payments
  4. GlaxoSmithKline, LLC. $72 1 payment
  5. Merck Sharp & Dohme Corporation $35 2 payments
  6. La Jolla Pharmaceutical Company $22 1 payment

Every payment, record by record

What the payments were for General payments · program year 2024
  1. Food and Beverage $467 13 payments
Products named General payments · program year 2024
  1. EVENITY $118 1 payment
  2. MOUNJARO $96 1 payment
  3. ULTOMIRIS $90 3 payments
  4. SHINGRIX $72 1 payment
  5. ZERBAXA $35 2 payments
  6. RECARBRIO $35 2 payments
  7. Repatha $34 4 payments
  8. GIAPREZA $22 1 payment
  9. DIFICID $20 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 39 drugs

Part D claims

960

Median for Internal Medicine: 777

Drug cost

$19,787

Median for Internal Medicine: $73,373

Branded share of claims

28.6%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 38 $8,823
Albuterol Sulfate Hfa Albuterol Sulfate Brand 112 $3,043
Wixela Inhub Fluticasone Propion/Salmeterol Brand 15 $2,684
Atorvastatin Calcium Generic 86 $552
Diclofenac Sodium Generic 25 $541
Gabapentin Generic 47 $473
Losartan Potassium Generic 53 $446
Metoprolol Succinate Generic 29 $429
Levocetirizine Dihydrochloride Generic 20 $247
Amlodipine Besylate Generic 75 $182

The 10 drugs with the highest cost, of 39 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
EVENITY
  • Amgen Inc. $118
$118 — —
MOUNJARO
  • Lilly USA, LLC $96
$96 — —
ULTOMIRIS
  • Alexion Pharmaceuticals, Inc. $90
$90 — —
SHINGRIX
  • GlaxoSmithKline, LLC. $72
$72 — —
Repatha
  • Amgen Inc. $34
$34 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

13 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record